EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Syntheses of carbon 14 penem antibacterials fce 22101 and fce 22891



Syntheses of carbon 14 penem antibacterials fce 22101 and fce 22891



Journal of Labelled Compounds & Radiopharmaceuticals 24(1): 41-48



The synthesis of FCE 22101 (sodium (5R,6S)-6-[(1R)-hydroxyethyl]-2-carbamoyloxymethylpenem-3-carboxylate) labelled with carbon-14 in the 2-position of the penem system ring was performed in eight steps, using sodium salt [1-14C]glycollic acid 1 as the labelled starting material. The final product, penem [2-14C] FCE 22101 11, was obtained in an overall radiochemical yield of 21%, 98% radiochemically pure and with a specific activity of 641 MBq/mmol (17.3 mCi/mmol). The acetoxymethyl ester FCE 22891 12 was prepared by condensation of 11 with bromomethyl acetate, with a yield of 41%.

(PDF 0-2 workdays service: $29.90)

Accession: 006559708

Download citation: RISBibTeXText



Related references

In vitro and in vivo evaluation of the penem FCE 22101 and its orally absorbed ester FCE 22891. Giornale Italiano di Chemioterapia 30(2-3): 125-130, 1983

Synthesis and biological properties of sodium (5R, 6S, 8R)-6 alpha-hydroxyethyl-2-carbamoyloxymethyl-2-penem-3-carboxylate (FCE 22101) and its orally absorbed esters FCE 22553 and FCE 22891. Journal of Antibiotics 36(7): 938-941, 1983

FCE 22101, a new penem antibacterial, and its oral prodrug, FCE 22891. Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy. Los Angeles, California, 23-26 October 1988. Journal of Antimicrobial ChemoTherapy 23 Suppl C: 1-208, 1989

Symposium on fce 22101 a new penem antibacterial and its oral prodrug fce 22891 held at the twenty eighth interscience conference on antimicrobial agents and chemotherapy los angeles california usa october 23 26 1988. Journal of Antimicrobial Chemotherapy 23(SUPPL C): 1-203, 1989

Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101. Journal of Antimicrobial ChemoTherapy 25(3): 371-383, 1990

The disposition and urinary metabolism of carbon 14 labelled fce 22891 a pro drug of fce 22101 in animals. Journal of Antimicrobial Chemotherapy 25(1): 133-140, 1990

Pharmacokinetics of carbon 14 fce 22891 a penem antibiotic following oral administration to healthy volunteers. Antimicrobial Agents & Chemotherapy 36(9): 1958-1963, 1992

Toxicological profile of FCE 22101 and its orally available ester FCE 22891. Journal of Antimicrobial ChemoTherapy 23 Suppl C: 129-135, 1989

Pharmacokinetics and metabolism of FCE 22101 following its administration as the oral pro-drug FCE 22891. Journal of Antimicrobial ChemoTherapy 29(2): 179-185, 1992

Synthesis and antimicrobial spectrum of FCE 22101 and its orally available ester FCE 22891. Journal of Antimicrobial ChemoTherapy 23 Suppl C: 1-6, 1989

The disposition and urinary metabolism of 14C-labelled FCE 22891, a pro-drug of FCE 22101, in animals. Journal of Antimicrobial ChemoTherapy 25(1): 133-139, 1990

Rapid hydrolysis in vivo in man of FCE 22891, the orally absorbed ester of FCE 22101. Journal of Antimicrobial ChemoTherapy 25(3): 486-488, 1990

Fce 22891 oral penem. Drugs of the Future 16(4): 313-316, 1991

Pharmacokinetics of FCE 22891, a new oral penem. Antimicrobial Agents and ChemoTherapy 34(6): 1001-1006, 1990